Comparative Pharmacology
Head-to-head clinical analysis: AXUMIN versus JAYPIRCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXUMIN versus JAYPIRCA.
AXUMIN vs JAYPIRCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
JAYPIRCA (pirtobrutinib) is a selective, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). It binds to BTK, inhibiting its kinase activity, thereby blocking B-cell receptor signaling and reducing proliferation and survival of malignant B cells.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
The recommended adult dose is 15 mg orally once daily, with or without food.
None Documented
None Documented
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Terminal half-life approximately 15-20 hours in adults with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment).
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Primarily renal (80-90% as unchanged drug and minor metabolites); fecal <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical